|
Tuesday, 03 February 2009 00:00 |
|
Response Genetics, Inc. RGDX, a company focused on the development and sale of molecular diagnostic tests for cancer, announced today it has signed a nonexclusive license with Roche Diagnostics for the use of Response Genetics’ patented PCR analysis to assess human epidermal growth factor type 2 (HER2) gene expression. The accurate measurement of HER2 gene expression can assist physicians with treatment decisions for patients with cancers in tissues such as breast. For complete story, click here.
|
Recent News 
